Abstract

A Clinical, Prospective, Randomized, Double-blind Trial Comparing the Efficacy of a Combination vs. Control as an Oral Intervention for Chloasma

Chloasma is an acquired, chronic hypermelanosis that remains difficult to improvement. The combination of collagen peptide (CP), soy peptide (SP) and an aqueous extract of Chrysanthemum morifolium (AECM) has been proven to have antioxidant and anti-melanogenesis activity in vitro and in an animal model. In this study, we evaluated the efficacy of the combination versus a control as an oral intervention for chloasma by a non-invasive clinical method. Sixty-two subjects were recruited and randomly assigned to two groups: test group and control group. The test group was administered the combination every day for 60 days according to the manufacturer’s instructions. Two types of methods — an instrument-based measurement and clinical grading — were conducted at each time point to evaluate the improvement in the chloasma. The instrumental results revealed a significant decrease in skin yellowness at 60 days compared with the control group, and the clinical-grading results were in good agreement. Additionally, after administration of the combination, skin hydration exhibited an increasing trend compared with the control group. No side effects were observed during the study. The combination was effective in reducing the hyperpigmentation of subjects with chloasma. The combination oral intake might prevent chloasma from worsening.


Author(s):

Juntao Kan, Jianwei Liu, Yinbei Chen, Jun Du



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+